US 2013/0158090 A1 · METRONIDAZOLE ESTERS FOR TREATING ROSACEA

Abstract

A compound of formula (I): is described, as well as enantiomers, pharmaceutically acceptable salts thereof, for its use as a medicament.

Claims13

Dependent claims

A method for treating an inflammatory pathology, said method comprising administrating to a subject in need of such treatment, a compound of formula (I) below:

or an enantiomer or pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

13/806,732Filed 29 Jun 2011

Priority

FR 10/5524229 Jun 2010

Published

20 Jun 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07D 233/94
Attached in position 4 or 5: with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 31/4164
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: 1,3-Diazoles
A61P 17/00
Drugs for dermatological disorders

Abstract

A compound of formula (I): is described, as well as enantiomers, pharmaceutically acceptable salts thereof, for its use as a medicament.

Claims13

Dependent claims

A method for treating an inflammatory pathology, said method comprising administrating to a subject in need of such treatment, a compound of formula (I) below:

or an enantiomer or pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Metronidazole esters for treating rosacea

Life of this patent

Abstract

Claims13

Metronidazole esters for treating rosacea

Life of this patent

Abstract

Claims13